Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With EGFR Mutation”

743 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 743 results

Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Not applicableUnknownNCT04909073
What this trial is testing

Observational Study of Afatinib 30 mg Daily

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Testing effectiveness (Phase 2)Looking for participantsNCT07323641
What this trial is testing

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 60
Early research (Phase 1)UnknownNCT05555212
What this trial is testing

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 72
Testing effectiveness (Phase 2)UnknownNCT03799094
What this trial is testing

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Clifford Hospital, Guangzhou, China 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07710612
What this trial is testing

ABSK043 Combined With Osimertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Abbisko Therapeutics Co, Ltd 72
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Not applicableStudy completedNCT01790217
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Large-scale testing (Phase 3)UnknownNCT02859077
What this trial is testing

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Early research (Phase 1)Active Not RecruitingNCT05163028
What this trial is testing

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Who this might be right for
Non Small Cell Lung CancerColorectal CancerPancreatic Cancer+4 more
HUYABIO International, LLC. 42
Testing effectiveness (Phase 2)Looking for participantsNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06728865
What this trial is testing

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain Metastases+2 more
Li-kun Chen 70
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Not applicableStudy completedNCT04795245
What this trial is testing

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 805
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Early research (Phase 1)Study completedNCT03846310
What this trial is testing

Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of Lung+1 more
Arcus Biosciences, Inc. 77
Large-scale testing (Phase 3)Active Not RecruitingNCT04695925
What this trial is testing

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Who this might be right for
Non-small Cell CarcinomaEGFR Gene Mutation
Li Zhang, MD 294
Next Page